<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02162862</url>
  </required_header>
  <id_info>
    <org_study_id>CCFA 13050045</org_study_id>
    <nct_id>NCT02162862</nct_id>
  </id_info>
  <brief_title>Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease</brief_title>
  <official_title>Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease: A Novel Adjunctive Therapy for Chronic Inflammatory Illness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eva Szigethy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Crohn's and Colitis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if either a targeted type of talk therapy (Phase I)
      or medication, Wellbutrin, (Phase II) improve sleep disturbance and/or fatigue in individuals
      with Inflammatory Bowel Disease (IBD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study, sponsored by the Crohn's and Colitis Foundation of America, intends to
      provide information about the feasibility and effectiveness of treatments designed to lessen
      fatigue and improve sleep among youth with Crohn's disease (CD). Obtaining good sleep is
      vital in leading a healthy life. For youth with Inflammatory Bowel Disease (IBD), good sleep
      is key as patients are psychically and psychologically developing and maturing. Previous work
      suggests that 42% of youth with CD experience poor sleep: difficulty falling asleep,
      disruption in sleep, early morning awakening, or an absence of feeling refreshed after sleep.
      Poor sleep can negatively affect ones physical health, mental health, and stress level - each
      minimizing ones quality of life.

      Participants in the study range from 15-30 years old, live with CD, and experience sleep
      disturbances, targeting 100 participants. Additionally, a healthy control group, 30
      participants, is included for comparison. The study contains two phases and takes place over
      a 12-week period. Phase one involves partaking in 3-8 sessions of Brief Behavioral Therapy
      for Sleep in IBD (BBTS-I) with study clinician. The treatment teaches self-management
      techniques and sleep interventions through self-hypnosis/relaxation and reflection. After the
      treatment, participants are reevaluated. Those who respond well to the treatment are offered
      1-2 booster sessions, those who do not show improvement move on to phase two.

      In phase two, participants are offered an 8-week course of bupropion-sustained release
      (BUP-SR). BUP-SR reduces fatigue, depression, and inflammation, and enhances REM sleep. The
      prescribed dosage will increase from 100mg to 300 mg (150 mg 2x a day). Participant's
      characterization measures are assessed at the start, midpoint, and finish of the study to
      measure changes in sleep, fatigue, and mood. Also at these times, blood work is done in hopes
      of gaining an understanding of the cause of CD. At each of the three assessments,
      participants are asked to wear a wristwatch device for 7 days that records: total sleep time,
      wakefulness, and daytime information on napping and sleep hygiene. In addition, participants
      are asked to keep a brief sleep diary for a 7-day period. This study hopes to provide new
      treatments to increase the quality of life, primarily by improving sleep in patients with CD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2013</start_date>
  <completion_date type="Actual">June 30, 2016</completion_date>
  <primary_completion_date type="Actual">June 30, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Multidimensional Fatigue Inventory (MFI) for Each Arm</measure>
    <time_frame>Baseline (week 0) to end of study (week 14)</time_frame>
    <description>MFI score range is 0-100. Higher score indicates higher level of fatigue.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Baseline in Pittsburgh Sleep Quality Index (PSQI) for Each Arm</measure>
    <time_frame>Baseline (week 0) to end of study (week 14)</time_frame>
    <description>PSQI score range is 0-21 with higher score indicating greater sleep disturbance.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Sleep Disturbance</condition>
  <condition>Fatigue</condition>
  <condition>Inflammatory Bowel Disease</condition>
  <arm_group>
    <arm_group_label>Behavioral Counseling</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I). This treatment phase focuses on treating insomnia, a nighttime component of sleep disturbance delivered in 1:1 sessions which can be completed in person or by phone, except for initial session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Behavioral counseling + bupropion-SR</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I) plus bupropion-SR (bupropion-Sustained Release). 8-week trial of bupropion-SR (target dose: 200-300 mg/day). bup-SR, a noradrenergic dopaminergic reuptake inhibitor (NDRI). NDRI has been shown to improve fatigue and rapid eye movement-sleep (REM) in medically ill populations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The healthy control group includes individuals who are free of physical and psychiatric illness between the ages of 15-30.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral Counseling</intervention_name>
    <arm_group_label>Behavioral Counseling</arm_group_label>
    <arm_group_label>Behavioral counseling + bupropion-SR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupropion-SR</intervention_name>
    <arm_group_label>Behavioral counseling + bupropion-SR</arm_group_label>
    <other_name>Wellbutrin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  IBD Group:

               -  Biopsy confirmed Crohn's Disease

               -  Qualifying scores on Multidimensional Fatigue Inventory and Pittsburgh Sleep
                  Quality Index

          -  Healthy Volunteer Group:

               -  Does not meet any exclusion criteria

        Exclusion Criteria:

          -  IBD Group:

               -  Meeting criteria for active alcohol or substance abuse or dependence

               -  Current ongoing treatment with Wellbutrin

               -  Females who are pregnant or plan to become pregnant within three months

               -  Sleep disorder such as apnea, restless leg syndrome or use of Continuous positive
                  airway pressure therapy (C-PAP)/Bilevel positive airway pressure (Bi-PAP)

               -  Current IBD flare requiring hospitalization with intravenous steroid treatment

               -  Other acute medical conditions or a history of chronic inflammatory condition
                  other than IBD

               -  Hemoglobin &lt;10 with age and gender adjustments

               -  History of seizure disorder

               -  Acute infection within seven days

          -  Healthy Volunteer Group:

               -  History or current episode of psychiatric disorder by Diagnositic and Statistical
                  Manual (DSM-IV)

               -  Current ongoing treatment with psychoactive medications

               -  Medications for sleep in previous two weeks

               -  Females who are pregnant or plan to become pregnant within three months

               -  History of IBD, epilepsy, rheumatoid arthritis, lupus

               -  Sleep disorder such as apnea, restless leg syndrome or use of Continuous positive
                  airway pressure therapy (C-PAP)/Bilevel positive airway pressure (Bi-PAP)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva Szigethy, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Presbyterian University Hospital of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2014</study_first_submitted>
  <study_first_submitted_qc>June 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2014</study_first_posted>
  <results_first_submitted>June 28, 2017</results_first_submitted>
  <results_first_submitted_qc>August 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 13, 2017</results_first_posted>
  <last_update_submitted>August 14, 2017</last_update_submitted>
  <last_update_submitted_qc>August 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Eva Szigethy</investigator_full_name>
    <investigator_title>Associate Professor of Psychiatry, Pediatrics, and Medicine</investigator_title>
  </responsible_party>
  <keyword>Inflammatory Bowel Disease</keyword>
  <keyword>Physical Illness</keyword>
  <keyword>Wellbutrin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Dyssomnias</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment took place at the Digestive Disorders Clinic at Presbyterian Hospital in Pittsburgh, PA. Recruitment began 11/13/13 and ended 2/18/16.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Healthy Control</title>
          <description>The healthy control group included individuals who were free of physical and psychiatric illness between the ages of 15-30.</description>
        </group>
        <group group_id="P2">
          <title>Behavioral Counseling</title>
          <description>Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I). This treatment phase focuses on treating insomnia, a nighttime component of sleep disturbance delivered in 1:1 sessions which can be completed in person or by phone, except for initial session.
Behavioral Counseling
Within this arm, some participants offered bupropion-SR (bupropion-Sustained Release). 8-week trial of bupropion-SR (target dose: 200-300 mg/day). bup-SR, a noradrenergic dopaminergic reuptake inhibitor (NDRI). NDRI has been shown to improve fatigue and rapid eye movement-sleep (REM) in medically ill populations.
bupropion-SR</description>
        </group>
        <group group_id="P3">
          <title>Behavioral Counseling + Bupropion</title>
          <description>Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I) plus bupropion-SR (bupropion-Sustained Release). 8 -week trial of bupropion-SR (target dose: 200-300mg/day). Bupropion-SR, a noradrenergic dopaminergic reuptake inhibitor (NDRI). NDRI has been shown to improve fatigue and rapid eye movement sleep (REM) in medically ill populations.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject did not feel the med was needed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Behavioral Counseling</title>
          <description>Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I). This treatment phase focuses on treating insomnia, a nighttime component of sleep disturbance delivered in 1:1 sessions which can be completed in person or by phone, except for initial session.
Behavioral Counseling</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Individuals free of physical and psychiatric illness.</description>
        </group>
        <group group_id="B3">
          <title>Behavioral Counseling + Bupropion</title>
          <description>Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I) plus bupropion-SR (bupropion-Sustained Release). 8-week trial of bupropion-SR (target dose: 200-300 mg/day). bup-SR, a noradrenergic dopaminergic reuptake inhibitor (NDRI). NDRI has been shown to improve fatigue and rapid eye movement-sleep (REM) in medically ill populations.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="33"/>
            <count group_id="B4" value="99"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.7" spread="4.7"/>
                    <measurement group_id="B2" value="23.5" spread="4.3"/>
                    <measurement group_id="B3" value="23.96" spread="5.76"/>
                    <measurement group_id="B4" value="23.7" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Multidimensional Fatigue Inventory (MFI) for Each Arm</title>
        <description>MFI score range is 0-100. Higher score indicates higher level of fatigue.</description>
        <time_frame>Baseline (week 0) to end of study (week 14)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Behavioral Counseling</title>
            <description>Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I). This treatment phase focuses on treating insomnia, a nighttime component of sleep disturbance delivered in 1:1 sessions which can be completed in person or by phone, except for initial session.
Behavioral Counseling
Within this arm, some participants offered bupropion-SR (bupropion-Sustained Release). 8-week trial of bupropion-SR (target dose: 200-300 mg/day). bup-SR, a noradrenergic dopaminergic reuptake inhibitor (NDRI). NDRI has been shown to improve fatigue and rapid eye movement-sleep (REM) in medically ill populations.
bupropion-SR</description>
          </group>
          <group group_id="O2">
            <title>Healthy Control</title>
            <description>The healthy control group included individuals who were free of physical and psychiatric illness between the ages of 15-30.</description>
          </group>
          <group group_id="O3">
            <title>Behavioral Counseling + Bupropion</title>
            <description>8-week trial of bupropion-SR (target dose: 200-300 mg/day). bup-SR, a noradrenergic dopaminergic reuptake inhibitor (NDRI). NDRI has been shown to improve fatigue and rapid eye movement-sleep (REM) in medically ill populations.
bupropion-SR</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Multidimensional Fatigue Inventory (MFI) for Each Arm</title>
          <description>MFI score range is 0-100. Higher score indicates higher level of fatigue.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.727" spread="13.843"/>
                    <measurement group_id="O2" value="-1.828" spread="5.8"/>
                    <measurement group_id="O3" value="16.367" spread="13.962"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.005</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.005</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.102</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Baseline in Pittsburgh Sleep Quality Index (PSQI) for Each Arm</title>
        <description>PSQI score range is 0-21 with higher score indicating greater sleep disturbance.</description>
        <time_frame>Baseline (week 0) to end of study (week 14)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Behavioral Counseling</title>
            <description>Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I). This treatment phase focuses on treating insomnia, a nighttime component of sleep disturbance delivered in 1:1 sessions which can be completed in person or by phone, except for initial session.
Behavioral Counseling</description>
          </group>
          <group group_id="O2">
            <title>Healthy Control</title>
            <description>The healthy control group included individuals who were free of physical and psychiatric illness between the ages of 15-30.</description>
          </group>
          <group group_id="O3">
            <title>Behavioral Counseling + Bupropion</title>
            <description>Within this arm, some participants offered bupropion-SR (bupropion-Sustained Release). 8-week trial of bupropion-SR (target dose: 200-300 mg/day). bup-SR, a noradrenergic dopaminergic reuptake inhibitor (NDRI). NDRI has been shown to improve fatigue and rapid eye movement-sleep (REM) in medically ill populations.
bupropion-SR</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Baseline in Pittsburgh Sleep Quality Index (PSQI) for Each Arm</title>
          <description>PSQI score range is 0-21 with higher score indicating greater sleep disturbance.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.857" spread="3.928"/>
                    <measurement group_id="O2" value="-.154" spread="1.69"/>
                    <measurement group_id="O3" value="6.571" spread="3.696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.005</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.646</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.005</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The study was conducted over a period of 2 years. Each subject participated in the study for 4 months. No adverse events were reported for any subjects during their time in the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Healthy Control</title>
          <description>The healthy control group included individuals who were free of physical and psychiatric illness between the ages of 15-30.</description>
        </group>
        <group group_id="E2">
          <title>Behavioral Counseling</title>
          <description>Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I). This treatment phase focuses on treating insomnia, a nighttime component of sleep disturbance delivered in 1:1 sessions which can be completed in person or by phone, except for initial session.
Behavioral Counseling</description>
        </group>
        <group group_id="E3">
          <title>Behavioral Counseling + Bupropion</title>
          <description>Participants offered bupropion-SR (bupropion-Sustained Release). 8-week trial of bupropion-SR (target dose: 200-300 mg/day). Bup-SR, a noradrenergic dopaminergic reuptake inhibitor (NDRI). NDRI has been shown to improve fatigue and rapid eye movement-sleep (REM) in medically ill populations.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There were no limitations to this study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Eva Szigethy</name_or_title>
      <organization>University of Pittsburgh Medical Center</organization>
      <phone>412-802-6696</phone>
      <email>szigethye@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

